Carteolol ophthalmic solution is indicated, alone or in combination with other intraocular pressure lowering agents, for the treatment of chronic open angle glaucoma and ocular hypertension.

Carteolol is a long-acting nonselective beta-adrenergic blocking agent with moderate intrinsic sympathomimetic activity, no membrane stabilizing activity and low lipid solubility.Carteolol appears to be comparable in efficacy to betaxolol and timolol, but offers no clear advantages over either agent.

Ocular administration can result in some systemic absorption; the precautionary statements regarding oral and ocular administration are the same. It is contraindicated in patient with bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, hypersensitivity to carteolol, overt cardiac failure, severe sinus bradycardia.

Transient eye irritation, burning, tearing, conjunctival hyperemia, and edema have been reported in approximately 25% of patients following ocular administration of carteolol. Other effects reported include blurred or cloudy vision, light sensitivity, decreased night vision, ptosis, redness, abnormal corneal staining, blepharoconjunctivitis, and corneal sensitivity.

Adults: glaucoma: one drop BID

Store at 15 to 25℃ and protect from light